Romy E D Lamers1, Maarten Cuypers2, Marieke de Vries3, Lonneke V van de Poll-Franse4, J L H Ruud Bosch5, Paul J M Kil6. 1. Department of Urology, Elisabeth Hospital Tilburg, Tilburg, The Netherlands. Electronic address: r.lamers@elisabeth.nl. 2. Department of Social Psychology, Tilburg University, Tilburg, The Netherlands. 3. Institute for Computing and Information Sciences (iCIS), Social and Cultural Psychology, Behavioral Science Institute, Radboud University, Nijmegen, The Netherlands. 4. Netherlands Cancer Registry, Comprehensive Cancer Organisation Netherlands (CCON), Eindhoven, The Netherlands; Department of Medical Psychology and Neuropsychology, CoRPS-Center of Research on Psychology in Somatic Diseases (CoRPS), Tilburg University, Tilburg, The Netherlands. 5. Department of Urology, University Medical Center Utrecht, Utrecht, The Netherlands. 6. Department of Urology, Elisabeth Hospital Tilburg, Tilburg, The Netherlands.
Abstract
PURPOSE: To determine the effect of a decision aid (DA) on treatment preferences and to investigate which patient preferences are important for final treatment preferences. We also determined if the patient׳s treatment decision was influenced by the urologist׳s treatment preference. PATIENTS AND METHODS: Between August 2014 and July 2015, newly diagnosed patients with low-/intermediate-risk prostate cancer were offered to use a web-based DA after diagnosis. Treatment preferences and patient׳s values were extracted from the DA. Urologists׳ treatment preferences were indicated at the time of inclusion. RESULTS: We included 181 patients, of whom 21% preferred active surveillance, 33% radical prostatectomy, 10% brachytherapy, 3% external beam radiotherapy, and 34% did not indicate a specific preferred treatment option after DA use (missing N = 6). Among 67%, treatment preference before DA use did not change after DA use. In men who chose active surveillance after DA use, 97% (37/38) preferred to postpone unnecessary treatment. For radical prostatectomy, 91% (52/57) of the patients valued tumor removal, and for brachytherapy, 88% (15/17) valued incontinence worse than bowel complaints. For 64% (missing N = 21) of the patients, urologists indicated one specific preferred treatment option as most suitable for the patient concerned. Agreement between final treatment decision and urologist׳s preference was lower (κ = 0.68) than between final treatment decision and preferred treatment after DA use (κ = 0.82). CONCLUSION: Most patients with prostate cancer chose the treatment in accordance with the post-DA preference and to a lesser extent the urologists preference; implications of this are prospectively investigated in an ongoing study.
PURPOSE: To determine the effect of a decision aid (DA) on treatment preferences and to investigate which patient preferences are important for final treatment preferences. We also determined if the patient׳s treatment decision was influenced by the urologist׳s treatment preference. PATIENTS AND METHODS: Between August 2014 and July 2015, newly diagnosed patients with low-/intermediate-risk prostate cancer were offered to use a web-based DA after diagnosis. Treatment preferences and patient׳s values were extracted from the DA. Urologists׳ treatment preferences were indicated at the time of inclusion. RESULTS: We included 181 patients, of whom 21% preferred active surveillance, 33% radical prostatectomy, 10% brachytherapy, 3% external beam radiotherapy, and 34% did not indicate a specific preferred treatment option after DA use (missing N = 6). Among 67%, treatment preference before DA use did not change after DA use. In men who chose active surveillance after DA use, 97% (37/38) preferred to postpone unnecessary treatment. For radical prostatectomy, 91% (52/57) of the patients valued tumor removal, and for brachytherapy, 88% (15/17) valued incontinence worse than bowel complaints. For 64% (missing N = 21) of the patients, urologists indicated one specific preferred treatment option as most suitable for the patient concerned. Agreement between final treatment decision and urologist׳s preference was lower (κ = 0.68) than between final treatment decision and preferred treatment after DA use (κ = 0.82). CONCLUSION: Most patients with prostate cancer chose the treatment in accordance with the post-DA preference and to a lesser extent the urologists preference; implications of this are prospectively investigated in an ongoing study.
Authors: Liza van Deursen; Anke Versluis; Rosalie van der Vaart; Lucille Standaar; Jeroen Struijs; Niels Chavannes; Jiska J Aardoom Journal: JMIR Cancer Date: 2022-06-14
Authors: Berend Jan van der Wilk; Ben M Eyck; Manon C W Spaander; Roelf Valkema; Sjoerd M Lagarde; Bas P L Wijnhoven; J Jan B van Lanschot Journal: Dig Surg Date: 2018-09-18 Impact factor: 2.588
Authors: G E Collée; B J van der Wilk; J J B van Lanschot; J J Busschbach; L Timmermans; S M Lagarde; L W Kranenburg Journal: Curr Oncol Rep Date: 2020-07-28 Impact factor: 5.075
Authors: Margaret Fitch; Veronique Ouellet; Kittie Pang; Simone Chevalier; Darrel E Drachenberg; Antonio Finelli; Jean-Baptiste Lattouf; Carmen Loiselle; Alan So; Simon Sutcliffe; Simon Tanguay; Fred Saad; Anne-Marie Mes-Masson Journal: J Patient Exp Date: 2020-06-11
Authors: Maarten Cuypers; Romy E D Lamers; Paul J M Kil; Lonneke V van de Poll-Franse; Marieke de Vries Journal: Support Care Cancer Date: 2018-05-12 Impact factor: 3.603
Authors: Romy E D Lamers; Maarten Cuypers; Marieke de Vries; Lonneke V van de Poll-Franse; J L H Ruud Bosch; Paul J M Kil Journal: World J Urol Date: 2021-07-17 Impact factor: 4.226